Symptomatic effect and serum gastrin level after treatment with proton pump inhibitor in GERD investigation in partial responder to potassium-competitive acid blocker
Not Applicable
- Conditions
- GERD
- Registration Number
- JPRN-UMIN000030941
- Lead Sponsor
- Ishihara Gastroenterology Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients with warning findings such as vomiting subject to endoscopic examination, gastrointestinal bleeding (including findings of hematemesis, venous drainage, anemia, etc.), and rapid weight loss. (2) Patients with malignant lesions confirmed or suspected of malignant lesions. (3) A patient with a history of gastrointestinal resection and vagotomy. (4) Patients with irritable bowel syndrome. (5) Patients who are difficult to participate in this study due to mergers of severe liver disease, kidney disease, heart disease etc. (6) Pregnant women, lactating women or lactating women who may be pregnant. (7) Patients who other doctors judged inappropriate as subjects of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the change in FSSG total score before and 4 weeks after treatment with Esomeprazole
- Secondary Outcome Measures
Name Time Method 1. Score change of each of the reflux score and exercise failure score after 2 or 4 weeks evaluated by the FSSG questionnaire 2. Total core change after 2 weeks evaluated by FSSG questionnaire 3. Therapeutic reactivity after 2 or 4 weeks evaluated in the GOS questionnaire 4. Serum gastrin level change before and after esomeprazole administration 5. tolerability during administration of both drugs